<DOC>
	<DOCNO>NCT01272141</DOCNO>
	<brief_summary>The patient ask join clinical research study find lapatinib , agent target protein , call epidermal growth factor receptor ( EGFR ) surface cancer cell combination everolimus , agent target protein cancer cell , call mammalian target rapamycin ( mTOR ) effective metastatic triple negative breast cancer longer controlled standard chemotherapy .</brief_summary>
	<brief_title>A Study Lapatinib Combination With Everolimus Patients With Advanced , Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologically confirm ER ( ) , PR ( ) , HER2 ( ) locally advanced metastatic breast cancer Disease progression follow prior first line cytotoxic chemotherapy metastatic setting At least 1 lesion measurable Response Evaluation Criteria Solid Tumors ( RECIST ) criteria Age &gt; 18 year old Female Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Left ventricular ejection fraction ( LVEF ) &gt; 50 % Absolute neutrophil count ( ANC ) &gt; 1500/mm3 ; platelet &gt; 100,000/mm3 ; hemoglobin &gt; 9 g/dL ; serum creatinine &lt; 1.5x upper limit normal ( ULN ) ; total bilirubin &lt; 1.5x ULN , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5x ULN Patients must recover acute late effect prior surgery , radiotherapy antineoplastic therapy Patients legal representative must able read , understand provide inform consent participate trial . Patients childbearing potential agree use effective form contraception study 90 day follow last dose study medication ( effective form contraception oral contraceptive double barrier method ) Patients current active hepatic biliary disease ( except patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Patients active infection fever &gt; 101.3 Fahrenheit within 3 day first schedule day protocol treatment Patients active central nervous system ( CNS ) metastasis . Patients stable CNS disease , undergone radiotherapy least 4 week prior plan first protocol treatment stable dose corticosteroid 3 week eligible trial History prior malignancy within past 5 year except curatively treat basal cell carcinoma skin cervical intraepithelial neoplasia two consecutive normal pap smear 6 month apart Patients receive radiotherapy 25 % bone marrow ; patient receive radiotherapy target lesion within 4 week entry Patients receive concurrent investigational therapy Peripheral neuropathy &gt; = Grade 2 Patients pregnant lactate Any medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . History allogeneic transplant Known HIV Hepatitis B C ( active , previously treat )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Estrogen receptor ( ER ) /progesterone receptor ( PR ) /human epidermal growth factor receptor 2 ( HER2 ) -negative breast cancer</keyword>
</DOC>